Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × OTHER × Genetic Counseling × Clear all

Phase

Status

Completed 7 Recruiting 5 Enrolling by invitation 2 Unknown 1 Terminated 1 Suspended 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cancer Risk Syndrome 1

Interventions

pembrolizumab 194 Cyclophosphamide 178 Nivolumab 169 Radiotherapy 158 Carboplatin 125 Paclitaxel 101 Dexamethasone 99 Cisplatin 99 Radiosurgery 90 Magnetic Resonance Spectroscopy 88 Surveys and Questionnaires 82 Ipilimumab 78 durvalumab 74 Lenalidomide 72 atezolizumab 69 Doxorubicin 69 Rituximab 65 Gemcitabine 64 Radiation 62 venetoclax 61 fludarabine 61 Bevacizumab 61 Standard of Care 58 Docetaxel 56 Radiotherapy, Intensity-Modulated 55 Oxaliplatin 54 Capecitabine 53 Specimen Handling 50 Fluorouracil 50 Etoposide 50

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04323774 2025-12-12

AYA-RISE

Dana-Farber Cancer Institute

Phase NA Active not recruiting

Cancer Risk Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡